secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001411685-25-000028
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen updates fasedienol Phase 3 timelines: PALISADE-3 data Q4 2025, PALISADE-4 H1 2026
--------------------------------------------------------------------------------

- PALISADE-3 topline data remains on track for Q4 2025; PALISADE-4 now expected in H1 2026.
- Positive PALISADE-2 results (2023) plus success in either PALISADE-3 or -4 could support NDA submission.
- Protocol enhancements include site training, surveillance, and subject selection to replicate PALISADE-2 success.
- CEO cites strong patient/physician enthusiasm and growing unmet need in social anxiety disorder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000028/0001411685-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000028/vtgn-20250602.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer